TY - JOUR T1 - Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis JF - medRxiv DO - 10.1101/2020.07.10.20150680 SP - 2020.07.10.20150680 AU - Umesha Boregowda AU - Abhilash Perisetti AU - Arpitha Nanjappa AU - Mahesh Gajendran AU - Hemant Goyal Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/14/2020.07.10.20150680.abstract N2 - Introduction Tocilizumab is an anti-interleukin-6 antibody that has been used for the treatment of severe coronavirus disease 2019 (COVID-19). However, the concrete evidence of its benefit in reducing the mortality in severe COVID-19 is lacking. Therefore, we performed a systematic review and meta-analysis of relevant studies that compared the efficacy of Tocilizumab in severe COVID-19 vs. standard of care alone.Methods Literature search for studies that compared ‘Tocilizumab’ and ‘Standard of care’ in the treatment of COVID-19 was done using major online databases from December 2019 to June 14th, 2020. Search words ‘ Tocilizumab,’ ‘anti-interleukin-6 antibody,’ and ‘COVID-19’ or ‘coronavirus 2019’ in various combinations were used. Articles in the form of abstracts, letters without original data, case reports, and reviews were excluded. Data was gathered on an excel sheet, and statistical analysis was performed using Review Manager 5.3.Results Five studies were eligible from 693 initial studies, including 3,641 patients (64% males). There were thirteen retrospective studies and three prospective studies. There were 2,488 patients in the standard of care group (61.7%) and 1,153 patients (68.7%) in the Tocilizumab group. The death rate in the tocilizumab group, 22.4% (258/1153), was lower than the standard of care group, 26.21% (652/2,488) (Pooled odds ratio 0.57 [95% CI 0.36-0.92] p=0.02). There was a significant heterogeneity (Inconsistency index= 80%) among the included studies.Conclusion The addition of Tocilizumab to the standard of care might reduce the mortality in severe COVID-19. Larger randomized clinical trials are needed to validate these findings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding available for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research did not require IRB approval since it is a literature reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in this manuscript is available freely on online databases mentioned in the manuscriptCOVID 19coronavirus disease 2019SARSSevere Acute Respiratory SyndromeSARS-CoV-2Severe acute respiratory syndrome coronavirus-2ARDSAcute respiratory distress syndromeOROdds ratioI2Inconsistency indexTCZTocilizumabSOCStandard of careRCTRandomized controlled trialsG-CSFGranulocyte stimulating factorMCP-1Monocyte chemoattractant protein 1,TNFTumor necrosis factorACE2Angiotensin-converting enzymes 2CRSCytokine release syndromeSDStandard DeviationCKDChronic Kidney DiseaseNANot applicableCOPDChronic Obstructive Pulmonary DiseaseTCZTocilizumabHHydroxychloroquineL/RLopinavir/RitonavirR*RibavirinRRemdesivirOOseltamivirSSpike protein ER -